Alcobra Ltd (ADHD) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $16. Cantor Fitzgerald advised their investors in a research report released on Jun 7, 2016.
Alcobra Ltd closed down -0.06 points or -1.09% at $5.44 with 67,890 shares getting traded on Friday. Post opening the session at $5.47, the shares hit an intraday low of $5.32 and an intraday high of $5.54 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug MG01CI to treat Attention Deficit Hyperactivity Disorder (ADHD) a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs higher divorce rates lower levels of socioeconomic attainment lower academic achievement unemployment and work place deficits increased risks for motor vehicle accidents greater likelihood of additional psychiatric disorders increased criminal activity and incarceration and higher rates of substance use and abuse. MG01CI product has completed phase two studies.